Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Conditions:   Biochemically Recurrent Prostate Carcinoma;   Prostate Adenocarcinoma Interventions:   Biological: Durvalumab;   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   University of Washington;   National Cancer Institute (NCI);   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

A challenge in the diagnosis of prostate pathology is the numerous benign mimics of prostatic adenocarcinoma. Most of these lesions have no clinical significance but may be misinterpreted as cancer in biopsy specimens. In this review we describe the features of some of the more common benign mimics and discuss how they can be distinguished from carcinoma. The diagnostic entities most commonly associated with a false positive diagnosis of cancer are the atrophic group of lesions that include simple atrophy, partial atrophy and post-atrophic hyperplasia.
Source: Diagnostic Histopathology - Category: Pathology Authors: Source Type: research
Conclusions: 68Ga PSMA-11 PET/MR is overall highly concordant with surgical pathology and provides complementary information to multiparametric MR for assessment of extent of cancer involvement in prostate gland and pelvic nodes. Patients without nodal involvement on PET in our cohort had a low probability of biochemical recurrence in two years after imaging.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate: PSMA PET and others Source Type: research
Conclusions: [68Ga]-NeoBOMB1 uptake allowed detection of primary and metastatic lesions in patients with different tumor types, although tumor-specific uptake was variable and warrants further investigation. [68Ga]-NeoBOMB1 was well tolerated, with no related adverse events, consistent with the safety profile in previous studies. Whole-body dosimetry data were consistent with previous results in patients with gastrointestinal stromal tumors.1 The findings support further clinical development of NeoB (formerly known as NeoBOMB1) in a theragnostic approach using [68Ga]-NeoB to identify patients with GRPR-positive malignancie...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Oncology & amp; Translational III Source Type: research
Conclusion: PET/CT has proven to be an effective tool in guiding the use of specific targets for drug delivery to spontaneously occurring disease. The result of this work validates results shown in previous mice studies. Comparative oncology enables researches to further understand the mechanisms of human disease and fast-track drug development. The utility of HBP as a transport mechanism for chemotherapy drugs using PET/CT to determine personalised targets is currently being investigated in canine models.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Technologist Poster Session Source Type: research
Conclusions: Of the solid tumors and metastatic sites evaluated, a high detection rate was observed (39/47 non-prostatic tumors showed focal uptake). These findings correlate with the series of cases reported in the literature. Although our population has heterogeneous diagnoses, renal tumors showed greater avidity of the radiotracer. With these findings, the expression of PSMA in a variety of non-prostatic malignancies, gives us the potential theragnostic application.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: PSMA and DCFPyL Source Type: research
CONCLUSION: The incidence of Prostate cancer was different between Baluch and Fars ethnicities in Iran. The lowest ASR of PCa was observed in Baluch ethnicity, however the possibility of underreporting due to less access in Baluch ethnicity cannot be ruled out. The Gleason distribution pattern was not concordant to the incidence distribution of Prostate cancer. PMID: 32406055 [PubMed - as supplied by publisher]
Source: Urology Journal - Category: Urology & Nephrology Authors: Tags: Urol J Source Type: research
In this report, we present a typical case of “double-negative” end-stage prostate cancer that morphologically resembled basal cell carcinoma of prostate, basaloid large nest type.
Source: Pathology Case Reviews - Category: Pathology Tags: Case Reviews Source Type: research
Prostate cancer with neuroendocrine (NE) differentiation can be classified into six categories: conventional adenocarcinoma with NE differentiation, adenocarcinoma with Paneth cell–like NE differentiation, carcinoid tumor, small cell carcinoma, large cell carcinoma, and mixed NE carcinoma-acinar adenocarcinoma. Mixed NE carcinoma-acinar carcinoma is a biphasic carcinoma characterized by the presence of NE (small or large cell) carcinoma and conventional acinar adenocarcinoma. In rare cases, these two components overlap without discrete classic small cell carcinoma or a usual prostate adenocarcinoma component, making ...
Source: Pathology Case Reviews - Category: Pathology Tags: Case Reviews Source Type: research
We present a case of metastatic acinar prostatic adenocarcinoma with neuroendocrine features with strong and diffuse synaptophysin expression, mimicking a metastatic neuroendocrine tumor. We review recognized prostatic neuroendocrine tumors, tumors with neuroendocrine differentiation requiring further investigation, relevant differential considerations, and recommended ancillary workup of challenging cases.
Source: Pathology Case Reviews - Category: Pathology Tags: Case Reviews Source Type: research
We describe a rare case of de novo metastatic adenosquamous carcinoma in a patient presenting with a markedly elevated serum prostate-specific antigen and multiple osteoblastic lesions. The prognosis for patients with adenosquamous carcinoma of the prostate has historically been dismal, with death occurring within 12 to 24 months of diagnosis.
Source: Pathology Case Reviews - Category: Pathology Tags: Case Reviews Source Type: research
More News: Adenocarcinoma | AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Prostate Cancer | Research